## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add <u>Friedman A</u>	1 0	Person*	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC.		ationship of Reporting Pe < all applicable) Director	rson(s) to Issuer 10% Owner
(Last) 6 HADASSA	(First) ST.	(Middle)	ORMP ]  3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022	-	Officer (give title below)	Other (specify below)
(Street) TEL AVIV, (City)	L3 (State)	6451306 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line) X	vidual or Joint/Group Filir Form filed by One Rej Form filed by More tha Person	porting Person
		Table I - Non-Do	erivative Securities Acquired, Disposed of, or Bene	ficially	Owned	

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	01/03/2022		Α		6,000	Α	(1)	6,000	D	
Common Stock	01/03/2022		<b>G</b> <sup>(2)</sup>		6,000	D	\$ <mark>0</mark>	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numb Derivati Securiti Acquire Dispose (D) (Inst and 5)	ve es ed (A) or ed of	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title an of Securiti Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy	\$13.89	01/03/2022		A		10,000		(3)	01/03/2032	Common Stock	10,000	\$0	10,000	D	
Stock Option (right to buy	\$13.89	01/03/2022		G <sup>(2)</sup>			10,000	(3)	01/03/2032	Common Stock	10,000	\$0	0	D	

## Explanation of Responses:

1. Represents Restricted Stock Units ("RSU5") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. These shares of common stock and stock options were transferred, for no consideration, to a trust with an independent trustee.

3. The Stock Option will vest in 4 installments as follows: 2,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

-				
	1	05	101	רכו
			171	

\*\* Signature of Reporting Person

/s/ Aviad Friedman

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.